GW Pharmaceuticals PLC closed at $175.80 in the latest trading session, marking a -0.01% move from the prior day. This change lagged the S&P 500's daily gain of 0.95%. Elsewhere, the Dow gained 0.94%, while the tech-heavy Nasdaq added 0.8%.
Prior to today's trading, shares of the company had lost 6.08% over the past month. This has lagged the Medical sector's gain of 5.28% and the S&P 500's gain of 2.47% in that time.
GWPH will be looking to display strength as it nears its next earnings release. In that report, analysts expect GWPH to post earnings of -$0.13 per share. This would mark year-over-year growth of 89.68%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $63.37 million, up 1731.5% from the year-ago period.
It is also important to note the recent changes to analyst estimates for GWPH. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. GWPH is currently a Zacks Rank #2 (Buy).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 88, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Image: Bigstock
GW Pharmaceuticals PLC (GWPH) Stock Sinks As Market Gains: What You Should Know
GW Pharmaceuticals PLC closed at $175.80 in the latest trading session, marking a -0.01% move from the prior day. This change lagged the S&P 500's daily gain of 0.95%. Elsewhere, the Dow gained 0.94%, while the tech-heavy Nasdaq added 0.8%.
Prior to today's trading, shares of the company had lost 6.08% over the past month. This has lagged the Medical sector's gain of 5.28% and the S&P 500's gain of 2.47% in that time.
GWPH will be looking to display strength as it nears its next earnings release. In that report, analysts expect GWPH to post earnings of -$0.13 per share. This would mark year-over-year growth of 89.68%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $63.37 million, up 1731.5% from the year-ago period.
It is also important to note the recent changes to analyst estimates for GWPH. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. GWPH is currently a Zacks Rank #2 (Buy).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 88, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.